Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK - 9-13 November 2008
|
Ninth International Congress on Drug Therapy in HIV InfectionGlasgow, UK - 9-13 November 2008 |
|
J Int AIDS Soc 2008, 11(Suppl 1):29 doi:10.1186/1758-2652-11-S1-O29
JD Kowalska1, O Kirk1, A Mocroft2, L Høj1, N Friis-Møller1, P Reiss3 and JD Lundgren4
1 Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark 2 Royal Free Centre for HIV Medicine and Research Department of Infection & Population Health, London, UK 3 Academic Medical Center, Amsterdam, Netherlands 4 Copenhagen HIV Programme, University of Copenhagen; Centre for Viral Diseases/KMA, Rigshospitalet, Copenhagen, Denmark
BACKGROUND: With potentially life-long treatment of patients with HIV it is crucial to ensure antiretroviral treatment is used in such a way that adverse effects are reduced as much as possible.
METHODS: We illustrate methodology of the number needed to treat to harm (NNTH) using the recent findings from the D:A:D study (90% increased relative risk, RR = 1.90, of myocardial infarction [MI] in patients on abacavir compared with patients not receiving abacavir) [1]. We assume this RR remains constant across the range of underlying risk of MI. NNTH was calculated as 1/[(underlying risk of MI × 1.90) - underlying risk of MI], where the underlying risk of MI is calculated for the next 5 years using a parametric statistical model based on the Framingham score [2] [http://www.cphiv.dk/TOOLS/tabid/282/Default.aspx].
SUMMARY OF RESULTS: The relationship between NNTH and underlying risk of MI is exponential whereas the relationship between absolute risk increase and underlying risk of MI is linear (Figure 1). The NNTH shows a steep decrease from 185 to 5 when the underlying risk of MI increases from 0.6% to 20%. The lowest NNTH values are observed in the high risk group, while the most dynamic changes in NNTH is in the low risk group. A low risk profile was used to illustrate the relationship between NNTH and underlying risk of MI in clinical terms; a male, aged 40, non-smoker with no diabetes, no ECG-left ventricle hypertrophy (ECG-LVH), systolic blood pressure (sBP) of 120 mmHg, total cholesterol (TC) of 170 mg/dL (4.4 mmol/L) and HDL of 60 mg/dL (1.5 mmol/L). For this profile, underlying risk of MI is 0.1% and NNTH = 1,111. The NNTH drops from 1,111 to 555 if diabetes, ECG-LVH or TC = 240 mg/dl (6.2 mmol/L) is diagnosed (Table 1). The NNTH drops further to 370 for sBP = 160 mmHg or HDL = 35 mg/dl (0.9 mmol/L) and to 277 for smoking.When two risk components are unfavourable at the same time the NNTH drops from 1,111 to around 100 for most pairs, except smoking and unfavourable HDL, for which NNTH = 69. The NNTH becomes 7 and the underlying risk of MI 15% when all risk factors are unfavourable. Practical tools (including 3D graphs) to explore these relations and guide interventions for individual patients have been developed.
Table 1 (abstract P29)| Change in factors contributing to underlying risk | Underlying risk of MI in 5 years (%) | NNTH |
| Example low risk profile (described in text) | 0.1 | 1111 |
| If total cholesterol 240 mg/dL (6.2 mmol/L) | 0.2 | 555 |
| If diabetes | 0.2 | 555 |
| If ECG-LVH | 0.2 | 555 |
| If sBP 160 mmHg | 0.3 | 370 |
| If HDL 35 mg/dL (0.9 mmol/L) | 0.3 | 370 |
| If smoking | 0.4 | 277 |
| If HDL and total cholesterol unfavourable | 0.8 | 138 |
| If smoking and diabetes | 1.1 | 101 |
| If smoking and total cholesterol unfavourable | 1.0 | 111 |
| If smoking and sBP 160 mmHg | 1.3 | 85 |
| If smoking and HDL unfavourable | 1.6 | 69 |
| If smoking and lipids unfavourable | 3.1 | 35 |
| If all unfavourable combined (excluding ECG-LVH) | 10.1 | 11 |
| If all unfavourable combined (including ECG-LVH) | 15.0 | 7 |
CONCLUSIONS: It is possible to increase NNTH values for any group of patients on abacavir by decreasing the underlying risk of MI. Therefore, if underlying risk of MI can be reduced, the NNTH for a given therapy will increase, meaning that the therapy can be administered to more people without causing additional harm.
REFERENCES:
1. Sabin C, et al: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 Apr 26;371(9622):1417-26. Epub 2008 Apr 2.
2. Anderson KM, et al: Cardiovascular disease risk profiles. Am Heart J. 1991 Jan;121(1 Pt 2):293-8.
2008-11-10
1758-2652-11-S1-O29
Copyright © 2008 Kowalska et al; licensee BioMed Central Ltd
This information is designed to support, not replace, the relationship that exists between you and your doctor.
1980, 2009. AEGiS.